DNTH | Dianthus Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	26.37 - 27.81
52 Week Range	0.6800 - 33.77
Beta	2.10
Implied Volatility	114.96%
IV Rank	26.67%
Day's Volume	131,601
Average Volume	274,887
Shares Outstanding	29,354,300
Market Cap	781,411,466
Sector	Healthcare
Industry	Biotechnology
IPO Date	2018-06-21

Valuation
Profitability
Growth
Health
P/E Ratio	-13.72
Forward P/E Ratio	N/A
EPS	-1.94
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	53
Country	USA
Website	DNTH

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.

*Chart delayed

Analyzing fundamentals for DNTH we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is strong. For more detailed analysis please see DNTH Fundamentals page.

Watching at DNTH technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on DNTH Technicals page.